Korsana Biosciences, Inc. Common Stock
KRSA
86 hedge funds and large institutions have $237M invested in Korsana Biosciences, Inc. Common Stock in 2019 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 35 increasing their positions, 15 reducing their positions, and 16 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 15
6% more capital invested
Capital invested by funds: $223M → $237M (+$14M)
0.23% more ownership
Funds ownership: 71.06% → 71.29% (+0.23%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
9% less funds holding
Funds holding: 95 → 86 (-9)
56% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$1.03M |
| 2 |
UBS AM
Chicago,
Illinois
|
+$362K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$270K |
| 4 |
SPC
Slate Path Capital
New York
|
+$256K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$144K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BM
Bridger Management
New York
|
-$11.8M |
| 2 |
SCM
Sarissa Capital Management
Greenwich,
Connecticut
|
-$2.86M |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$899K |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$258K |
| 5 |
USAA
United Services Automobile Association
San Antonio,
Texas
|
-$250K |
KRSA Hedge Fund Activity: Q3 2019 in Review
86 of the 4,575 institutional investors tracked by Wall St. Rank reported a position in Korsana Biosciences, Inc. Common Stock (KRSA) for Q3 2019, worth a combined $237M — up 6.3% from $223M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of KRSA and 7 opened new positions — a net loss of 9 holders — while 15 trimmed existing stakes and 35 added.
The largest buyer was Camber Capital Management, adding an estimated $1.03M. The largest seller was Bridger Management, exiting entirely with an estimated $11.8M sold.
- 86 institutional investors held Korsana Biosciences, Inc. Common Stock (KRSA) as of Q3 2019, down from 95 in Q2 2019.
- Funds reported $237M of Korsana Biosciences, Inc. Common Stock stock for Q3 2019, up 6.3% quarter-over-quarter.
- 7 funds opened new Korsana Biosciences, Inc. Common Stock positions in Q3 2019 and 16 closed out, a net change of -9 holders.
- The largest Korsana Biosciences, Inc. Common Stock buyer in Q3 2019 was Camber Capital Management, an estimated $1.03M added.
- The largest Korsana Biosciences, Inc. Common Stock seller in Q3 2019 was Bridger Management, an estimated $11.8M sold.
Based on aggregated 13F filings for Q3 2019.